Poly(lactide-co-glycolide) encapsulated hydroxyapatite microspheres for sustained release of doxycycline |
| |
Authors: | Xiaoyun Wang Hui XuYanqiu Zhao Shaoning Wang Hiroya AbeMakio Naito Yanli LiuGuoqing Wang |
| |
Affiliation: | a School of Pharmacy, Shenyang Pharmaceutical University, 103, Wenhua Road, Shenyang 110016, PR China b Department of Pharmacy, Shandong Drug & Food Vocational College, Science & Technology Town, Hightech Industrial Development Zone, Weihai 264210, PR China c School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103, Wenhua Road, Shenyang 110016, PR China d Joining and Welding Research Institute, Osaka University, 11-1, Mihogaoka, Ibaraki, Osaka 567-0047, Japan |
| |
Abstract: | The purpose of this study was to prepare a poly(lactide-co-glycolide) (PLGA) encapsulated hydroxyapatite microspheres (HAP-MSs) as injectable depot for sustained delivery of Doxycycline (Doxy). Doxy loaded HAP-MSs (Doxy-HAP-MSs) were encapsulated with PLGA by solid-in-oil-in-water (S/O/W) emulsion-solvent evaporation technique, the effects of the PLGA used (various intrinsic viscosity and LA/GA ratio) and ratio of PLGA/HAP-MSs on the formation of Doxy-HAP-MSs and in vitro release of Doxy were studied. The results showed that sustained drug release without obvious burst was obtained by using PLGA encapsulated HAP-MSs as the carrier, also the drug release rate could be tailored by changing the ratio of PLGA/HAP-MSs, or PLGA of various intrinsic viscosities or LA/GA ratio. Lower ratio of PLGA/HAP-MSs corresponded faster Doxy release, e.g. for the microspheres of PLGA/HAP-MSs ratio of 8 and 0.25, the in vitro Doxy release percents at the end of 7days were about 23% and 76%, respectively. Higher hydrophilicity (higher ratio of GA to LA) and lower molecular weight of PLGA corresponded to higher Doxy release rates. For in vivo release study, PLGA encapsulated HAP-MSs were subcutaneously injected to the back of mice, and the results showed good correlation between the in vivo and in vitro drug release. Meanwhile, the plasma Doxy levels after subcutaneous administration of PLGA encapsulated Doxy-HAP-MSs were relatively lower and steady compared to that of the un-encapsulated microspheres. In conclusion, PLGA encapsulated HAP-MSs may be a potential vehicle for the sustained delivery of Doxy. |
| |
Keywords: | Doxycycline Hydroxyapatite Microspheres Poly(lactide-co-glycolide) Sustained drug release |
本文献已被 ScienceDirect 等数据库收录! |
|